SAM #N0018926QB059

Preclinical Research Services for Broad-Spectrum Antiviral CENi Compounds

This opportunity involves preclinical research and development of Cap-dependent endonuclease inhibitors (CENis) as broad-spectrum antiviral therapeutics for the Department of Defense, specifically supporting the Naval Medical Research Command. - Government Buyer: - Department of the Navy, NAVSUP Fleet Logistics Center Norfolk, BUMED FM&C Directorate - Naval Medical Research Command (NMRC) - OEMs and Vendors: - University of Texas Medical Branch (UTMB) is the named research facility and sole source contractor - Products/Services Requested: - Research support services for preclinical development of CENis, including: - Selection of lead CENi candidates - In vitro and in vivo efficacy studies - Compound characterization and optimization - Project management and oversight - Delivery of 100 CENi compounds (50 anti-arenavirus, 50 anti-bunyavirus) for screening - Provision of 3 lead CENi compounds for in vivo studies against Lassa virus, Lujo virus, and Crimean-Congo hemorrhagic fever virus - Labor and Other Direct Costs (ODCs) as contract line items - Unique/Notable Requirements: - Research must address viruses requiring biosafety level 4 (BSL-4) containment - Quarterly progress reports and a final report within 90 days of completion - Work performed at UTMB, with oversight and acceptance by NMRC at Fort Detrick and Silver Spring, MD - Place of Performance and Delivery: - University of Texas Medical Branch (UTMB) - Naval Medical Research Command at Fort Detrick, MD - Naval Medical Research Center, Silver Spring, MD - Contracting office at NAVSUP Fleet Logistics Center Norfolk, VA - Period of Performance: - 36 months (3 years) from contract award

Description

The preclinical development of Cap-dependent endonuclease inhibitors (CENi), a class of small molecules, as broad-spectrum antiviral therapeutics. The scope of this project includes all activities required to select lead CENi candidates, including in vitro and in vivo efficacy studies and characterization and optimization of lead compounds. This includes Research Support expertise regarding the preclinical development of cap-dependent endonuclease inhibitors (CENis) with viruses that require biosafety level 4 (BSL-4) containment to support the Naval Medical Research Command in Fort Detrick, MD. This work will be performed over a 36-month period.

View original listing